Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 16, 2024LeukemiaOpen Access

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results

View Full Paper
Ask AI
Bookmark
Share

Authors

Jorge E. CortésJorge E. CortésAugusta University HealthKSKoji SasakiThe University of Texas MD Anderson Cancer CenterDKDong‐Wook KimUniversity Health Network

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cortés et al. (2024) studied this question.

synapsesocial.com/papers/68e69af9b6db643587620afahttps://doi.org/10.1038/s41375-024-02278-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results2023 · 53 citations
  2. 2Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial2021 · 208 citations
  3. 3A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs2021 · 347 citations
  4. 4Exposure–Efficacy Analysis of Asciminib in Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase2022 · 37 citations